One-year randomized study of the endometrial safety and bleeding pattern of 0.25 mg drospirenone/0.5 mg 17β-estradiol in postmenopausal women.

Conclusions The low-dose, 0.25 mg DRSP/0.5 mg E2 dose combination met the criteria for endometrial safety and demonstrated a favorable risk/benefit profile in this 1-year, double-blind, randomized study of postmenopausal women. PMID: 23531117 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/23531117?dopt=Abstract

Source: Climacteric - May 11, 2013 Category: Geriatrics Authors: Genazzani AR, Schmelter T, Schaefers M, Gerlinger C, Gude K Tags: Climacteric Source Type: research